Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03364348
Recruitment Status : Recruiting
First Posted : December 6, 2017
Last Update Posted : March 18, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
George W. Sledge Jr., Stanford University

Brief Summary:
This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as utomilumab, trastuzumab emtansine, and trastuzumab may interfere with the ability of tumor cells to grow and spread.

Condition or disease Intervention/treatment Phase
HER2 Positive Breast Carcinoma Recurrent Breast Carcinoma Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Drug: Utomilumab Drug: Trastuzumab Drug: Trastuzumab Emtansine Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

Estimate the maximum tolerated dose (MTD) and determine the recommended dose (RP2D) of utomilumab in combination with ado-rastuzumab emtansine (T-DM1) or trastuzumab in subjects with HER2 positive advanced breast cancer.

SECONDARY OBJECTIVES:

  • Determine the objective tumor response (ORR)
  • Determine the time to tumor response (TTR)
  • Determine the duration of response (DR)
  • Determine progression free survival (PFS)
  • Assess the safety and tolerability of utomilumab in combination with ado-trastuzumab emtansine or trastuzumab

OUTLINE: Patients are randomized to 1 of 2 cohorts.

COHORT 1: Dose 1: Utomilumab 20 mg IV + ado-trastuzumab emtansine (T-DM1) 3.6 mg/kg IV every 3 weeks. Dose 2: Dose Level 2 - Utomilumab 100 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks

COHORT 2: Dose 1: Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. Dose Level 2 - Utomilumab 100 mg IV + trastuzumab 6 mg/kg IV every 3 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1B Dose Escalation Trial of Human Anti 4 1BB Agonistic Antibody Utomilumab (PF 05082566) in Combination With Ado Trastuzumab Emtansine or Trastuzumab in Patients With HER2 Postive Advanced Breast Cancer
Actual Study Start Date : October 30, 2017
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Cohort 1 (Ado-trastuzumab emtansine + utomilumab)
Utomilumab at escalating doses of 20 mg and 100 mg will be given intravenously in combination with the FDA-approved dose and schedule of ado-trastuzumab emtansine (3.6 mg/kg IV) every 3 weeks.
Drug: Utomilumab
Given IV
Other Names:
  • 4-1BB Agonist Monoclonal Antibody PF-05082566
  • PF-05082566
  • PF-2566

Drug: Trastuzumab Emtansine
Given IV
Other Names:
  • Ado Trastuzumab Emtansine
  • Kadcyla
  • PRO132365
  • RO5304020
  • T-DM1
  • Trastuzumab-DM1
  • Trastuzumab-MCC-DM1
  • Trastuzumab-MCC-DM1 Antibody-Drug Conjugate
  • Trastuzumab-MCC-DM1 Immunoconjugate

Experimental: Cohort 2 (trastuzumab + utomilumab)
Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 2).
Drug: Utomilumab
Given IV
Other Names:
  • 4-1BB Agonist Monoclonal Antibody PF-05082566
  • PF-05082566
  • PF-2566

Drug: Trastuzumab
Given IV
Other Names:
  • ABP 980
  • Anti-c-ERB-2
  • Anti-c-erbB2 Monoclonal Antibody
  • Anti-ERB-2
  • Anti-erbB-2
  • Anti-erbB2 Monoclonal Antibody
  • Anti-HER2/c-erbB2 Monoclonal Antibody
  • Anti-p185-HER2
  • c-erb-2 Monoclonal Antibody
  • HER2 Monoclonal Antibody
  • Herceptin
  • Herceptin Biosimilar PF-05280014
  • Herceptin Trastuzumab Biosimilar PF-05280014
  • MoAb HER2
  • Monoclonal Antibody c-erb-2
  • Monoclonal Antibody HER2
  • PF-05280014
  • rhuMAb HER2
  • RO0452317
  • Trastuzumab Biosimilar ABP 980
  • Trastuzumab Biosimilar PF-05280014




Primary Outcome Measures :
  1. Incidence of Dose-limiting toxicities (DLTs) [ Time Frame: 2 months ]
    Incidence of dose-limiting toxicities (DLTs) within the first 2 cycles (upbto 2 months) reported for the Dose-finding Cohorts 1 (ado-trastuzumab emtansine) and 2 (trastuzumab). Subjects lost-to-follow-up before completion of first 2 cycles due to reasons unrelated to treatment-related adverse events are not evaluable for DLT.


Secondary Outcome Measures :
  1. Objective tumor response (ORR) [ Time Frame: 2 months ]

    Objective tumor response (ORR) after 2 cycles for subjects in Expansion Phase 1B Cohorts 1 (ado trastuzumab emtansine) and 2 (trastuzumab), per RECIST v1.1:

    • Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis < 10 mm). All target lesions must be assessed.
    • Partial Response (PR): ≥ 30% decrease in the sum of diameters of all target measurable lesions.
    • Progression Disease (PD): Increase in lesion size ≥ 5 mm and ≥ 20% increase in the sum of diameters of target measurable lesions.
    • Stable Disease (SD): All target lesions assessed, but not CR, PR, or PD.
    • Indeterminate. Progression has not been documented; and

      • 1+ target measurable lesions have not been assessed; or
      • Assessment methods inconsistent with baseline; or
      • 1+ target lesions cannot be measured accurately; or
      • 1+ target lesions excised or irradiated, and have not reappeared or increased.

  2. Time-to-tumor response (TTR) [ Time Frame: 4 months ]

    Time-to-tumor response (TTR), per RECIST v1.1, in subjects who have at least 1 on-study tumor assessment and respond within 4 months.

    RECIST v1.1:

    • Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis < 10 mm). All target lesions must be assessed.
    • Partial Response (PR): ≥ 30% decrease in the sum of diameters of all target measurable lesions.
    • Progression Disease (PD): Increase in lesion size ≥ 5 mm and ≥ 20% increase in the sum of diameters of target measurable lesions.
    • Stable Disease (SD): All target lesions assessed, but not CR, PR, or PD.
    • Indeterminate. Progression has not been documented; and

      • 1+ target measurable lesions have not been assessed; or
      • Assessment methods inconsistent with baseline; or
      • 1+ target lesions cannot be measured accurately; or
      • 1+ target lesions excised or irradiated, and have not reappeared or increased.

  3. Duration of response (DR) [ Time Frame: Up to 5 years ]

    Duration of response (DR) in subjects who have 1+ on-study tumor assessment and have a clinical response, through up to 5 years after treatment, per RECIST v1.1:

    • Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis < 10 mm). All target lesions must be assessed.
    • Partial Response (PR): ≥ 30% decrease in the sum of diameters of all target measurable lesions.
    • Progression Disease (PD): Increase in lesion size ≥ 5 mm and ≥ 20% increase in the sum of diameters of target measurable lesions.
    • Stable Disease (SD): All target lesions assessed, but not CR, PR, or PD.
    • Indeterminate. Progression has not been documented; and

      • 1+ target measurable lesions have not been assessed; or
      • Assessment methods inconsistent with baseline; or
      • 1+ target lesions cannot be measured accurately; or
      • 1+ target lesions excised or irradiated, and have not reappeared or increased

  4. Progression-Free survival (PFS) [ Time Frame: 6 months ]

    Progression-free survival (PFS) of subjects (percentage) who initiate treatment, reported as the number who remain alive without progression 6 months after treatment. Subjects withdrawn for treatment-related AEs, or lost to follow-up before 6 months, will report as the last date known alive

    RECIST v1.1 Progression Disease (PD): Increase in lesion size ≥ 5 mm and ≥ 20% increase in the sum of diameters of target measurable lesions.


  5. Adverse Event Incidence [ Time Frame: Up to 3 years ]
    Incidence of adverse events (not including laboratory abnormalities) while receiving treatment and within 30 days, reported by treatment group for severity (as graded by NCI CTCAE v5), seriousness (YES/no), and relationship to the study treatments

  6. Laboratory abnormality Incidence [ Time Frame: Up to 3 years ]
    Incidence of laboratory abnormalities reported by treatment group for severity (as graded by NCI CTCAE v5)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • History of biopsy proven HER2 overexpressing breast cancer and radiographic evidence of metastatic disease, or locally recurrent unresectable disease. The HER2 status can be determined either by immunohistochemistry (IHC) [IHC score, 3+] or by fluorescence in situ hybridization (FISH) [as defined by HER2/CEP 17 ratio ≥ 2.0, or HER2 copy number ≥ 6], or as otherwise defined by 2018 ASCO/CAP guidelines.
  • Cohort 1 subjects must have received trastuzumab and a taxane separately or in combination (those who previously received ado-trastuzumab emtansine may accrue to Cohort 2).
  • Subjects in Cohort 2 must have received at least 1 prior therapy including ado-trastuzumab emtansine.
  • Subjects who discontinued prior trastuzumab or ado trastuzumab emtansine due to progressive or refractory disease are eligible for enrollment
  • Available tumor samples. For eligibility, if no unstained slides remain, stained pathology slides may be reviewed at the treating institution. However, a tumor sample is required for research evaluations per the following (any of Item 1; 2; or 3, in order of preference).
  • A FFPE tumor tissue block from a de novo fresh tumor biopsy obtained during screening will be requested, though not mandated.
  • A recently obtained archival FFPE tumor tissue block (or 10 to 15 unstained slides) from a primary or metastatic tumor resection or biopsy if the following criteria are met:
  • The biopsy or resection was performed within 1 year of enrollment OR
  • The subject has not received any intervening systemic anti cancer treatment from the time the tissue was obtained and enrolled onto the current study. OR
  • Any archival FFPE tumor tissue block (or unstained slides) from primary tumor resection specimen (if not provided per above). The archival sample may have been collected at any time prior to the current study, regardless of any intervening therapy. If an FFPE tissue block cannot be provided, a minimum of 10 unstained slides (15 preferable) will be acceptable.
  • Subjects must have evaluable OR measurable disease, as defined by RECIST v1.1.
  • Performance status 0 to 1 (by Eastern Cooperative Oncology Group [ECOG] scale).
  • Laboratory parameters (must satisfy all): Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (≥ 1500/µL) Platelet count ≥ 100 × 109/L (≥ 100,000 /µL) Hemoglobin ≥ 9.0 g/dL; subjects on therapeutic anticoagulation are eligible if there is no bleeding and they are on a stable dose of anticoagulation therapy (eg, on Coumadin with an INR of 2 to 3) for at least 7 days before registration (prior to the start of therapy, or stable heparin or Factor Xa inhibitor dose) Serum creatinine ≤ 1.5 × the ULN or calculated creatinine clearance (by Cockcroft Gault formula) ≥ 60 mL/min Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN Bilirubin ≤ 1.5 × ULN
  • Subjects must not be pregnant or breastfeeding. A pregnancy test will be obtained if the subject is a woman of child bearing potential, defined as a sexually mature woman who has not undergone a hysterectomy or and/or bilateral oophorectomy or who has not been naturally postmenopausal for at least 24 consecutive months (ie, who has had menses at any time in the preceding 24 consecutive months) with 2 pregnancy tests, one at screening, and another immediately preceding the initiation of treatment.
  • Subjects must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment
  • Left ventricular ejection fraction determined by echocardiogram or multiple gated acquisition scan (MUGA) (cardiac scan) must be 50% or higher.

EXCLUSION CRITERIA:

  • Previously discontinued either trastuzumab or ado trastuzumab emtansine due to intolerance.
  • Received any other investigational agents within 30 days of registration.
  • Central nervous system (CNS) metastases, unless previously treated by either radiation therapy and/or surgical resection, clinically stable for at least 60 days and on a stable corticosteroid dose of ≤ 4 mg/day decadron (or equivalent steroid regimen) for at least 1 month. Subjects with a history of CNS metastases that are both treated and stably controlled are eligible if all of the following apply:
  • Therapy has been administered (surgery and/or radiation therapy);
  • There is no additional treatment planned for brain metastases;
  • The subject is clinically stable;
  • The subject is on a stable corticosteroid dose of ≤ 4 mg/day decadron (or equivalent steroid regimen) for at least 1 month.
  • Prior malignancy (other than in situ cervical cancer, or basal cell or squamous cell carcinoma of the skin), unless treated with curative intent and without evidence of disease for 3 years or longer
  • Administration of other prior anticancer therapies within 4 weeks of enrollment, except ongoing administration of a bisphosphonate drug or denosumab as treatment for bone metastasis
  • Toxicities related to prior anticancer treatment (except alopecia) that have not resolved to ≤ Grade 1 according to common terminology criteria for adverse events (CTCAE v5) before registration or prior to start of therapy
  • Currently receiving systemic antibiotic, antiviral, or antifungal therapy for the treatment of an active infection
  • Systemic corticosteroid therapy at doses of greater than prednisone 5 mg daily (or dose-equivalent chronic steroid regimen) for therapeutic and not adrenal replacement indications (maintenance steroid use for adrenal insufficiency is permitted). Acute emergency administration, topical applications, inhaled sprays, eye drops or local injections of corticosteroids are allowed.
  • History of bleeding diathesis
  • Any co morbid medical condition deemed by the treating or principal investigator to possibly put the subject at significant risk for toxicity.
  • Subject has known sensitivity to any of the products to be administered during dosing
  • Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of venous thromboembolism within prior 6 months.
  • Subject with reproductive potential who will not agree to use, during the study and for 60 days after the last dose of utomilumab or 6 months for ado trastuzumab emtansine or trastuzumab 2 highly effective method of contraceptive such as:
  • Implants
  • Injectables
  • Intrauterine devices (IUDs) such as copper T or Levonorgestrel releasing intrauterine system (LNG IUS)
  • Sexual abstinence
  • Vasectomized partner
  • Condom or occlusive cap (diaphragm or cervical/vault cap) supplemented with the use of a spermicide during treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364348


Contacts
Layout table for location contacts
Contact: Sinyoung Park 650-721-4485 sinyoung@stanford.edu

Locations
Layout table for location information
United States, California
Stanford University, School of Medicine Recruiting
Palo Alto, California, United States, 94304
Contact: Sinyoung Park    650-721-4485    sinyoung@stanford.edu   
Principal Investigator: George W. Sledge, MD         
Sponsors and Collaborators
George W. Sledge Jr.
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: George Sledge, MD Stanford Cancer Institute
Layout table for additonal information
Responsible Party: George W. Sledge Jr., Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT03364348    
Other Study ID Numbers: IRB-37299
NCI-2016-01881 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
IRB-37299 ( Other Identifier: Stanford IRB )
BRS0070 ( Other Identifier: OnCore )
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Breast Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Immunological
Trastuzumab
Ado-trastuzumab emtansine
Maytansine
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunoconjugates
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action